Diabetes mellitus type 2

Active Ingredient: Rosiglitazone

Indication for Rosiglitazone

Population group: only adults (18 years old or older)

Therapeutic intent: Curative procedure

Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:

as monotherapy:

in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance

as dual oral therapy in combination with:

metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin
a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylurea

as triple oral therapy in combination with:

metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

For this indication, competent medicine agencies globally authorize below treatments:

4 mg daily in 1 or 2 divided doses and after 8 weeks 4-8 mg daily in 1 or 2 divided doses

For:

Dosage regimens

Oral, 4 milligrams rosiglitazone, divided daily, 1 to 2 doses in total, over the duration of 8 weeks. Afterwards, oral, between 4 milligrams rosiglitazone and 8 milligrams rosiglitazone, divided daily, 1 to 2 doses in total.

Detailed description

Rosiglitazone therapy is usually initiated at 4 mg/day. This dose can be increased to 8 mg/day after eight weeks if greater glycaemic control is required.

In patients administered rosiglitazone in combination with a sulphonylurea, an increase in rosiglitazone to 8 mg/day should be undertaken cautiously following appropriate clinical evaluation to assess the patient’s risk of developing adverse reactions relating to fluid retention.

Rosiglitazone may be given once or twice a day.

Dosage considerations

Rosiglitazone may be taken with or without food.

Active ingredient

Rosiglitazone
Rosiglitazone is a selective agonist at the PPARγ (peroxisomal proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of anti-diabetic agents. It reduces glycaemia by reducing insulin resistance at adipose tissue, skeletal muscle and liver. Read more about Rosiglitazone

Related medicines

Summary of Product Characteristics (SPC) : AVANDIA Film-coated tablet

Structured Product Labeling (SPL/PLR) 2020: AVANDIA Film-coated tablet

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.